AstraZeneca Pharma India gets nod to import, distribute Sodium Zirconium Cyclosilicate powder

06 Mar 2025 Evaluate

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 for Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma).

Through this approval, Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients. The receipt of this permission paves way for the launch of Sodium Zirconium Cyclosilicate powder for oral suspension 5 g and 10 g (Lokelma) in India for the above specified indications, subject to the receipt of related statutory approvals, if any.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

8457.25 -64.25 (-0.75%)
24-Mar-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1785.30
Dr. Reddys Lab 1210.00
Cipla 1524.35
Lupin 2121.30
Zydus Lifesciences 926.60
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...